Congress targets hidden drug markups: PBMs must disclose pricing or face $1M fines
S. 526 — Pharmacy Benefit Manager Transparency Act of 2025 · Filed by Chuck Grassley (R-IA) · 14 cosponsors · Introduced Feb 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits pharmacy benefit managers (PBMs) from charging health plans more for drugs than they reimburse pharmacies for the same drugs while pocketing the difference, from arbitrarily clawing back pharmacy payments, or from shifting costs to pharmacies to offset federal reimbursement cuts. It requires PBMs to disclose all pricing, fees, and rebates to health plans and pharmacies, report annually to the FTC and HHS, and protects whistleblowers who report violations. The FTC gains enforcement authority with civil penalties up to $1 million per violation.
Why we flagged it
The bill's core mechanism is a transparency and anti-fraud mandate targeting PBM pricing practices, with FTC enforcement. It is regulatory reform aimed at reducing hidden intermediary markups in prescription drug distribution.
What the text implies
- PBMs may respond by consolidating (horizontal or vertical mergers) to achieve scale and offset compliance costs; the bill directs the FTC to study this risk but does not prevent it.
- Disclosure requirements may reveal competitive intelligence (rebate amounts, formulary strategies) that could accelerate industry consolidation or shift negotiating power.
- Whistleblower protections are broad (cover contractors, service providers, and perceived assistants) and bar predispute arbitration, creating new litigation exposure for PBMs and their affiliates.
- The affirmative defense (conduct necessary to comply with law, protect patient safety/access) is fact-intensive and may generate protracted litigation over PBM business practices.
- State attorneys general gain independent enforcement authority, creating parallel litigation risk and potential inconsistency in enforcement standards across states.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens benefit from reduced hidden markups in the drug supply chain, lower health plan costs (which reduce premiums), and more stable pharmacy networks. Whistleblower protections and FTC enforcement create accountability. The bill does not cap drug prices directly but removes a major source of hidden cost inflation.
Who stands to gain
- independent pharmacies (reduced clawbacks, more transparent reimbursement)
- health plans and employers (lower PBM markups, rebate pass-through)
- consumers (lower premiums and out-of-pocket costs from reduced intermediary inflation)
Named in the bill
Federal Trade Commission (FTC), Department of Health and Human Services (HHS), Pharmacy Benefit Managers (PBMs), Health plans, Pharmacies, Pharmaceutical manufacturers, State attorneys general, Comptroller General (GAO), Congressional Budget Office
Where it stands
14 cosponsors: 8 Republicans, 6 Democrats.
- Feb 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 11, 2025 — Referred to Senate Committee on Commerce, Science, and Transportation · Congress.gov: “Read twice and referred to the Committee on Commerce, Science, and Transportation”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
17 lobbying clients named this bill on 23 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $22,273,656 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 96% of bills with at least one filing.
Chuck Grassley, the sponsor, reported $49,167 in PAC receipts in the 2026 cycle.
- Pharmaceutical Care Management Association — $6,472,656 on 2 filings
- American Medical Association — $5,643,000 on 2 filings
- Elevance Health, Inc. — $4,010,000 on 2 filings
- Biotechnology Innovation Organization — $2,360,000 on 1 filing
- Alzheimer's Association — $1,800,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (23,719 characters) on Aug 31, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress targets hidden drug markups: PBMs must disclose pricing or face $1M fines” QuorumCivic. https://share.quorumcivic.app/bill/119/s526 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.